deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03380871

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Sponsor: BioNTech US Inc.

Conditions Carcinoma, Non-Small-Cell Lung Lung Cancer Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions Adjuvant Carboplatin NEO-PV-01 Pembrolizumab Pemetrexed
Updated 16 times since 2018 Last updated: Feb 24, 2021 Started: May 4, 2018 Primary completion: Oct 31, 2019 Completion: Feb 5, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Carcinoma, Non-Small-Cell Lung and Lung Cancer and is currently completed. BioNTech US Inc. leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Aug 2020 · 8 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2022 · 15 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE1

  5. Mar 2021 — Jun 2022 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Aug 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Dec 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

  6. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  7. May 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  8. Nov 2018 — May 2019 [monthly]

    Recruiting PHASE1

  9. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  10. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. Jan 2018 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BioNTech US Inc.
  • Merck Sharp & Dohme LLC
Data source: BioNTech SE

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations